熱門資訊> 正文
Janux治疗公司宣布PSMA-TRACTr JANX007 1a阶段剂量升级的中期临床数据和流水线计划的最新情况
2023-07-17 20:02
- Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS
- PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers
- JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities
- PK exposure demonstrated TRACTr activation with lack of TCE accumulation
- No treatment-emergent ADA titers observed
- Janux to host virtual investor event today at 4:00 PM Eastern Time
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。